21.71
-0.56(-2.51%)
Currency In USD
| Previous Close | 22.27 |
| Open | 20.16 |
| Day High | 22.02 |
| Day Low | 20 |
| 52-Week High | 24 |
| 52-Week Low | 2.88 |
| Volume | 395,398 |
| Average Volume | 714,813 |
| Market Cap | 778.41M |
| PE | 1.6 |
| EPS | 13.61 |
| Moving Average 50 Days | 18.15 |
| Moving Average 200 Days | 8.87 |
| Change | -0.56 |
If you invested $1000 in BioAge Labs, Inc. (BIOA) since IPO date, it would be worth $1,185.69 as of March 03, 2026 at a share price of $21.71. Whereas If you bought $1000 worth of BioAge Labs, Inc. (BIOA) shares 1 year ago, it would be worth $5,025.46 as of March 03, 2026 at a share price of $21.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 9:30 PM GMT
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
GlobeNewswire Inc.
Jan 22, 2026 3:30 AM GMT
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o
BioAge Announces Proposed Public Offering
GlobeNewswire Inc.
Jan 20, 2026 9:01 PM GMT
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o